[Argon plasma coagulation in treatment of hereditary hemorrhagic telangiectasia of the nasal mucosa].
Patients with hereditary hemorrhagic telangiectasia (M. Osler-Rendu-Weber disease) often suffer from recurrent epistaxis that poses considerable therapeutic problems. Dermoplasty, electrocoagulation, laser coagulation, iridium brachytherapy and systemic administration of estrogens have been proposed for treatment. Until recently argon plasma coagulation (APC) was not used in ENT surgery, but theoretical considerations render APC a promising therapeutic method for controlling nasal bleeding. Coagulation of tissue is limited to 1-2 mm of penetration and therefore risk of damage to adjacent tissue is low. Effects are best in tissues with high electric conductivity, especially for coagulating bleeding lesions and blood vessels. We have now treated four patients with telangiectasias in the nasal mucosa who had long histories of treatment for epistaxis. The patients were satisfied with the postoperative results and the frequency and intensity of bleeding were significantly reduced. Initial clinical experiences show that APC is a useful alternative for the treatment of bleeding telangiectasias in the nasal mucosa.
Bergler
W
W
Universitäts-HNO-Klinik, Fakultät für Klinische Medizin, Universität Heidelberg, Mannheim.
Götte
K
K
Riedel
F
F
Back
W
W
Hörmann
K
K
D000328:Adult; D002648:Child; D004844:Epistaxis / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017075:Laser Coagulation / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000601:surgery; D012008:Recurrence; D012086:Reoperation; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*
Die Argon-Plasma-Koagulation in der Behandlung von hereditären hämorrhagischen Teleangiektasien der Nasenschleimhaut.